Greenlight Biosciences Inc., a biotechnology company developing RNA-based solutions for agriculture and pharmaceutical applications, has received regulatory approval to begin the first phase 1/2 clinical trial of its COVID-19 vaccine candidate in Rwanda.
Read More
GreenLight Biosciences, which has a growing research and development presence in Research Triangle Park, has announced additional financing on its journey to becoming a publicly traded company.
Read More
GreenLight Biosciences, a Massachusetts-headquartered company with a growing R&D operations center in Research Triangle Park, plans to merge with a SPAC and take the company public. That’s good news for the Triangle, and Triangle workers.
Read More
In an interview with the North Carolina Biotechnology Center, Zarur said GreenLight’s 30-person Triangle operation is playing a significant role in developing its first RNA-derived product, a biopesticide that attacks the Colorado potato beetle. The hardy, hard-to-kill pest is often resistant to other pesticides.
Read More
GreenLight Biosciences Inc., which is developing RNA-based solutions for agriculture and pharmaceutical applications, has disclosed a $50 million first closing of its latest funding round.
Read More
